Copenhagen University Hospital Gentofte, Department of Dermato-venerology
Hellerup, 2900, Denmark
NCT Number: NCT01137188
Controlled data show that obesity is a risk factor for psoriasis and that psoriasis severity is correlated with the degree of overweight. No controlled interventional studies reporting on the effect of weight loss on psoriatic skin manifestations have been published and data from case reports are conflicting.
Patients with psoriasis demonstrate an increased susceptibility to atherosclerotic comorbidities such as arterial hypertension, coronary vascular disease, stroke, hyperlipidemia and type II diabetes and in severe psoriasis there is an increased risk of early death. Lately the role of inflammation in the atherosclerotic process has been highlighted and the link between psoriasis and atherosclerosis may be explained by the concomitant systemic inflammation in psoriasis. Similarly a state of low level inflammation is seen in obesity where macrophages and adipocytes begin to show overlap in function and gene expression. This leads to an increased migration of macrophages into the adipose tissue and an increased secretion of pro-inflammatory cytokines. In summary, these data and theoretical considerations suggest that weight loss in obese patients with psoriasis may improve skin manifestations and reduce the risk of atherosclerotic comorbidity.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Hellerup, 2900, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Low calorie diet containing 800-1000 kcal/day
Time frame: Baseline
Psoriasis area and severity index
Time frame: 4 weeks
Psoriasis area severity index
Time frame: 8 weeks
Psoriasis area severity index
Time frame: 12 weeks
Psoriasis area severity index
Time frame: 16 weeks
Psoriasis area severity index
Time frame: Baseline
Risk factors for comorbidity
Time frame: 4 weeks
Risk factors for comorbidity
Time frame: 8 weeks
Risk factors for comorbidity
Time frame: 12 weeks
Risk factors for comorbidity
Time frame: 16 weeks
Risk factors for comorbidity
University Hospital, Gentofte, Copenhagen
Other
Effect of Weight Loss on Skin Manifestations, Inflammatory Markers and Risk Factor for Comorbidity in Obese Patients With Psoriasis - a Randomized Cross-over Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04728165
Psoriasis, Skin Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT01778569
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05295979
Psoriasis, Skin Diseases
Hong Kong
View Trial DetailsNCT07712731
Psoriasis, Skin Diseases
Baotou, China
View Trial Details